Abstract：［Abstract］Objective To explore the clinical effect of different drug intervention on chronic obstructive pulmonary diseases（COPD）.M ethods 120 caseswith COPD in the stable period from September 2014 to December 2015 in our hospital were selected and divided into 4 groups according to the treatmentmeasures，30 cases in each group.The control group was given tiotropium bromide inhalation therapy，the atorvastatin treatment group was treated with atorvastatin oral therapy combined with tiotropium bromide inhalation therapy，the salmeterol and fluticasone treatment group was given salmeterol and fluticasone combined with tiotropium bromide inhalation therapy，the metoprolol treatment group was given metoprolol tablet oral therapy combined with tiotropium bromide inhalation therapy.Lung function，cat and mMRC scores，acute exacerbation frequency，the therapeutic effect of systemic comorbidities（cardiovascular and skeletal muscle atrophy，osteoporosis，depression and other）in each group within half a year was compared.Results The pulmonary function index of the salmeterol and fluticasone treatment group was higher than that of the control group，with significant difference （P＜0.05）.The pulmonary function index of the atorvastatin group and themetoprolol group had no significant difference in comparison with that of the control group （P＞0.05）.The symptom score in the salmeterol and fluticasone treatment group and the metoprolol treatment group was lower than that in the control group，acute exacerbation frequency withinhalf a year in the salmeterol and fluticasone treatment group and themetoprolol treatment group was less than that in the control group，with significant difference （P＜0.05）.There was no significant difference in the symptom score and acute exacerbation frequency within half a year between the atorvastatin treatment group and the control group（P＞0.05）. The therapeutic effective rate of cardiovascular complications of the atorvastatin treatment group and the metoprolol treatment group was higher than that in the control group and the salmeterol and fluticasone treatment group，with statistically significant difference （P＜0.05）.The therapeutic effective rate of skeletalmuscle atrophy comorbidity of the atorvastatin treatment group was higher than that of the other three groups，with significant difference（P＜0.05）.The therapeutic effective rate of osteoporosis and depression comorbidity of the atorvastatin treatment group，themetoprolol treatment group and the salmeterol and fluticasone treatment group showed no obvious decrease compared with that of the control group，without significant difference（P＞0.05）.Conclusion This study suggests that the combination ofmultiple drugs in the treatment of stable-stage COPD patientsmay achieve the best therapeutic effect of the disease and complications.
余江清； 丁月梅； 卢志军. 药物干预对慢性阻塞性肺疾病合并症的临床研究[J]. 中国当代医药, 2016, 23(20): 21-24.
YU Jiang-qing； DING Yue-mei； LU Zhi-jun. Clinical study of drug intervention on chronic obstructive pulmonary disease com plication. 中国当代医药, 2016, 23(20): 21-24.
Gan WQ，Man SF，Senthilselvan A，et al.Association between chronic obstructive pulmonary disease and systemic inflammation：a system atic review and a meta-analysis［J］. Thorax，2004，59（7）：574-580.
［3］
Dourado VZ，Tanni SE，Vale SA，et al.Systemic manifestations in chronic obstructive pulmonary disease［J］.J Bras Pneumol，2006，32（2）：161-171.
［4］
Celli BR，Cote CG，Marin JM，et al.The body-mass index，airflow obstruction，dyspnea，and exercise capacity index in chronic obstructive pulmonary disease［J］.N Engl JMed，2004，350（10）：1005-1012.
Luo Z，Liu CT，Wu C G，et al.Efficacy and safety of tiotropium bromide in the treatment of chronic obstructive pulmonary disease—a multi-center randomized clinical trial［J］.Sichuan Da Xue Xue Bao Yi Xue Ban，2015，46 （3）：485-487.
京公网安备 11010502046607号